|
1. Biologie
|
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
Holding Tobacco Companies Accountable for Deceptive Ads [Cancer Research Catalyst]
|
|
|
|
|
|
The
AACR and its Tobacco and Cancer Subcommittee is calling upon state and
city officials to raise the sale age of tobacco products to 21, pass
comprehensive smoke-free laws, increase individual states’ tobacco
taxes, ban kid-friendly flavors in all tobacco products, and increase
funding for tobacco prevention and cessation programs.
|
|
|
|
|
|
|
|
|
"Heat-not-burn" tobacco may be safer but still a risk: UK panel [Reuters]
|
|
|
|
|
|
The
Committee of Toxicology's report to Public Health England (PHE) said
people using such products were exposed to between 50 and 90 percent
fewer harmful and potentially harmful chemicals compared with
conventional cigarettes. But it was unable to quantify the risk
precisely versus conventional cigarettes or e-cigarettes because of
limited data.
|
|
|
|
|
|
|
3.8 Prévention - Alimentation
|
|
|
Disclosures in Nutrition Research [JAMA]
|
|
|
|
|
|
Authors
who have strong beliefs and make highly committed choices for diet or
other behaviors should not hesitate to disclose them. Doing so may help
everyone understand who is promoting what and why.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
How privacy policies affect genetic testing [MIT News]
|
|
|
|
|
|
Policies
that focus on the privacy risks of genetic testing, and ask for patient
consent to those risks, lead to a reduction in tests performed. But
policies that emphasize limits to further disclosure of genetic data
without consent, and explicitly define genetic data as the property of
the patient, lead to an increase in the number of tests performed.
|
|
|
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
Aduro Biotech Provides Update on CRS-207 Programs [Aduro]
|
|
|
|
|
|
Based
on preliminary results from its mesothelioma and ovarian studies, as
well as a business and commercial assessment, the company has determined
that it will not continue advancement of CRS-207 and will wind down
each of its trials in mesothelioma, ovarian and gastric cancer.
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
PsiOxus banks first milestone for BMS-backed cancer therapy [FierceBiotech]
|
|
|
|
|
|
NG-348
virus uses PsiOxus’ tumor-specific immuno-gene therapy (T-SIGn)
platform to arm the virus with two additional immuno-therapeutic
transgenes. The idea is that the virus replicates within cancer cells
and not within normal tissue, causing an inflammatory response that
encourages lymphocytes to collect and attack the tumor.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma [NCI]
|
|
|
|
|
|
FDA
based its approval on data from a single-arm clinical trial of 124
patients with mantle cell lymphoma whose cancer had progressed or
returned after at least one prior treatment regimen. All the patients
received acalabrutinib. The trial was sponsored by AstraZeneca, which
manufactures acalabrutinib.
|
|
|
|
|
|
|
5.7 SABCS
|
|
|
|
5.8.1 ASH - Communiqués
|
|
|
Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term [ASH]
|
|
|
|
|
|
The
first study addresses the use of direct oral anticoagulants (DOACs) to
safely treat dangerous blood clots in patients with cancer. The second
reports a significant breakthrough for reducing risks during the most
acute period of the rare blood disorder thrombotic thrombocytopenic
purpura (TTP). In the third and fourth studies, new drugs show
remarkable improvements over standard care for multiple myeloma and
chronic lymphocytic leukemia, respectively.
|
|
|
|
|
|
|
5.8.5 ASH - Myélome multiple
|
|
|
|
|
|
5.8.6 ASH - Leucémies
|
|
|
|
|
|
5.8.7 ASH - Lymphomes
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.7.1 Bioinformatique
|
|
|